X0303 4 2008-12-23 1 0000010081 BARR PHARMACEUTICALS INC BRL 0001237254 BOGDA MICHAEL BARR PHARMACEUTICALS, INC. 225 SUMMIT AVE MONTVALE NJ 07645 0 1 0 0 President & COO Common Stock 2008-12-23 4 D 0 17918 D 0 D Stock Options 36.3267 2008-12-23 4 D 0 2751 D 2011-08-08 Common Stock 2751 0 D Stock Options 26.58 2008-12-23 4 D 0 1 D 2012-08-07 Common Stock 1 0 D Stock Options 43.34 2008-12-23 4 D 0 43500 D 2013-07-30 Common Stock 43500 0 D Stock Options 35.01 2008-12-23 4 D 0 27144 D 2014-08-04 Common Stock 27144 0 D Stock Appreciation Rights 46.99 2008-12-23 4 D 0 30000 D 2015-07-27 Common Stock 30000 0 D Stock Appreciation Rights 48.80 2008-12-23 4 D 0 30000 D 2008-11-11 2016-07-26 Common Stock 30000 0 D Stock Appreciation Rights 49.49 2008-12-23 4 D 0 15000 D 2008-11-11 2017-03-07 Common Stock 15000 0 D Stock Appreciation Rights 55.81 2008-12-23 4 D 0 30000 D 2008-11-11 2017-08-09 Common Stock 30000 0 D Stock Appreciation Rights 49.22 2008-12-23 4 D 0 75000 D 2008-11-11 2018-03-04 Common Stock 75000 0 D Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 11,238 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $714,952.21. Option vested equally over a 3 year period from grant date These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $83,006.75, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $36.3267 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $39.92, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $26.58 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,007,460, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $854,764.56, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $585,300, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $531,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $255,150, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $320,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $55.81 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,296,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share. /s/ William T. McKee as Attorney in Fact for Michael Bogda 2008-12-29